Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC
in the setting of current standard of care treatments for COVID-19 infection in hospitalized
subjects with acute respiratory distress syndrome.